Jubilant Cadista Irbesartan tablets recalled due to failed dissolution
Jubilant Cadista Pharmaceuticals is recalling 28,560 bottles of Irbesartan 75 mg tablets nationwide due to failed dissolution specifications that may compromise drug efficacy.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is classified as FDA Class II with no reported hospitalizations or injuries. The failed dissolution specification constitutes a risk-of-harm to patients requiring blood pressure control, but no adverse events have been reported, making this a High-severity precautionary recall.
Plain-English summary
Jubilant Cadista Pharmaceuticals, Inc. is recalling 28,560 bottles of Irbesartan (Irbesartan Tablets, USP, 75 mg) nationwide. The recall affects lots IB120012A, IB120013A, and IB120014A with an expiration date of August 2022. The products are being recalled because they failed to meet dissolution specifications during quality testing, which may affect how the medication is absorbed in the body.
Irbesartan is an angiotensin II receptor blocker used to treat high blood pressure. If tablets do not dissolve properly, patients may not receive the intended dose of medication, potentially compromising therapeutic effectiveness.
Patients taking Irbesartan from the affected lots should not stop taking their medication without first consulting their healthcare provider. Those affected should contact their pharmacist or physician to determine if they have affected product and discuss alternative treatment options.
The FDA is monitoring this recall. For more information, consumers can contact Jubilant Cadista Pharmaceuticals, Inc., or visit the FDA's drug recalls website.
The recalled product
- Product
- IRBESARTAN (IRBESARTAN)
- Brand
- IRBESARTAN
- Manufacturer
- Jubilant Cadista Pharmaceuticals, Inc.
- Category
- Drug
- Hazard
- dissolution-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot #: IB120012A
- IB120013A
- IB120014A Exp. date 08/2022
UPCs (3)
- 0359746447304
- 0359746448301
- 0359746449308
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · IRBESARTAN
- HighIrbesartan Tablets Recalled Due to Out-of-Specification Dissolution
FDA (Drugs) · 2025-02-19
- HighIrbesartan Blood Pressure Tablets Recalled Due to Failed Dissolution
FDA (Drugs) · 2022-08-03
- HighLupin Irbesartan Tablets Recalled for Impurity Contamination
FDA (Drugs) · 2021-11-10
- ModerateIrbesartan 300 mg tablets recalled for impurity in active ingredient
FDA (Drugs) · 2021-11-10
- SevereIrbesartan Tablets Recalled for Impurity in Active Ingredient
FDA (Drugs) · 2021-11-10
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27